Status:

COMPLETED

Effects of Pioglitazone on Exogenous Carbohydrate Oxidation During Steady-State Exercise at High Altitude

Lead Sponsor:

United States Army Research Institute of Environmental Medicine

Conditions:

High Altitude

Eligibility:

MALE

18-39 years

Phase:

PHASE4

Brief Summary

Apparent hypoxia-induced insulin insensitivity along with alterations in glucose kinetics suggests reduction in glucose uptake by the peripheral tissue is a primary factor contributing to reductions i...

Detailed Description

This randomized crossover placebo controlled double blinded study will examine substrate oxidation and glucose kinetic responses to ingesting supplemental carbohydrate (glucose) during metabolically-m...

Eligibility Criteria

Inclusion

  • Men aged 18 - 39 years
  • Born at altitudes less than 2,100 m
  • Physically active (exercise minimum 2 days per week)
  • Have supervisor approval (permanent party military and civilians)
  • Willing to refrain from alcohol, smokeless nicotine products and dietary supplement use during study periods
  • Fully vaccinated against COVID-19

Exclusion

  • Born at altitudes greater than 2,100 m
  • Musculoskeletal injuries that compromise exercise capability
  • Metabolic or cardiovascular abnormalities, or gastrointestinal disorders
  • Taking medication that affects macronutrient metabolism and/or the ability to participate in strenuous exercise
  • Living in areas that are more than 1,200 m, or traveled to areas that are more than 1,200 m for five days or more within 2 months of data collection
  • Evidence of apnea or other sleeping disorders
  • Prior diagnosis of high altitude pulmonary edema or high altitude cerebral edema
  • Presence of asthma or respiratory tract infections
  • Smoking or vaping
  • Taking medications that interfere with oxygen delivery and transport
  • Anemia (HCT \<38% and HBG \<12.5 g/dL) and Sickle Cell Anemia/Trait
  • Blood donation within 8 weeks of beginning the study
  • Unwilling or unable to consume study diets or foods provided due to personal preference, dietary restrictions, and/or food allergies
  • Unwilling or unable to adhere to study physical restrictions

Key Trial Info

Start Date :

March 1 2023

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 1 2023

Estimated Enrollment :

9 Patients enrolled

Trial Details

Trial ID

NCT06164665

Start Date

March 1 2023

End Date

July 1 2023

Last Update

December 11 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

US Army Research Institute of Environmental Medicine

Natick, Massachusetts, United States, 01760